PKM and triple-negative breast carcinoma: According to these findings, we propose that ISLR is involved in the enhancement of the cellular antioxidant capacity when cancer cells are treated with cisplatin, and, as expected, blocking PKM2 activity is sufficient to sensitize triple-negative breast cancer to cisplatin both in vitro and in vivo.